 |
|
 |
Diagnostics |
|
|
Cardiovascular Diagnostics
Key Developments in Technologies and Markets
Publication Date May 2005
Publisher Cambridge Healthtech Advisors
Product Type Strategic Report
Pages 116
ISBN Number not applicable
Product Code CHA015
|
|
|
Summary
Cardiovascular Diagnostics: Key Developments in Technologies and Markets addresses the latest trends and developments in cardiovascular imaging and in vitro diagnostic techniques that will impact the market and the delivery of healthcare.
Cardiovascular diseases continue to be an enormous medical and cost burden on the health care system. As the rapidly aging population drives an increase in the incidence and prevalence of heart disease, the need for early detection and intervention will escalate dramatically. Cardiovascular Diagnostics: Key Developments in Technologies and Markets describes how the evolution of imaging technologies and discovery of new biomarkers is leading to continuous improvement in the ability to diagnose disease, monitor drug treatment, and identify patients at risk for cardiovascular events, such as heart attack and stroke.
The following advancements, as well as the companies competing in each area, are evaluated:
• A high clinical need exists for non-invasive angiography procedures to assess coronary artery blockages. The report evaluates new CT scan technology and its potential to deliver billions of dollars in savings to the health care system along with a lower risk of complications for the patient.
• Emerging cardiovascular biomarkers that will allow for better detection of patients at risk for developing coronary artery disease, including C-Reactive Protein, as well as a number of different inflammatory and ischemia biomarkers that are under investigation for faster diagnosis of myocardial infarction and to rule out acute coronary syndrome in patients presenting with chest pain.
• New radiopharmaceuticals agents being developed for cardiovascular nuclear medicine that promise to improve diagnosis.
• Advances in magnetic resonance (MR) imaging and other imaging modalities used in cardiovascular diagnostics.
• Early-stage developments in imaging unstable or ruptured plaque deposits in arteries.
• The emerging trend of cardio-theranostics, the pairing of a laboratory test with a cardiovascular drug.
|
Content
Executive Summary
Cardiovascular Imaging: Trends and Implications
In Vitro Cardiovascular Diagnostics: Trends and Implications
Chapter 1. Background Trends in Cardiovascular Disease
1.1 Cardiovascular Disease Statistics
Coronary Heart Disease
Congestive Heart Failure
Hypertension
Stroke
Cardiac Arrhythmias
Other Cardiovascular Disease
1.2 Prospects for Cardio-Theranostics
Chapter 2. Cardiovascular Imaging
2.1 Ultrasound
Competition
Market Trends and Developments
2.2 Magnetic Resonance
Competition
Market Trends and Developments
2.3 Computed Tomography
Competition
Market Trends
2.4 Nuclear Medicine
SPECT Imaging
-Competition and Market Trends
PET Imaging
-Competition and Market Trends
Chapter 3. Biomarkers for Cardiovascular Diagnostics
3.1 Biomarkers for Determining Risk in Coronary Artery Disease (CAD)
Description of Biomarkers for Risk of CAD
-C-Reactive Protein
-Lp-PLA2
-Homocysteine
-LDL Subclasses and Particle Size
-Lipoprotein (a)
-Apolipoprotein A and Apolipoprotein B
Medical and Economic Impact
Competition and Outlook
3.2 Biomarkers For Diagnosis of Acute Coronary Syndrome
Description of Current Markers for Acute Coronary Syndrome
-Creatine Kinase MB Isoenzymes (CK-MB)
-Troponin I and Troponin T
-Myoglobin
-Heart Fatty Acid Binding Proteins
-Ischemia-Modified Albumin
Potential Future Biomarkers for Acute Coronary Syndrome
-Blood Choline
-CD40 Ligand
-Chemoattractant Biomarkers
-Glutathione Peroxidase 1
-Myeloperoxidase
-Pregnancy-Associated Plasma Protein-A
-Serum Deoxyribonuclease I Activity
-Unbound Free-Fatty Acids
Medical and Economic Impact
Competition and Outlook
Biomarkers for Congestive Heart Failure
-Medical and Economic Impact
-Competition and Outlook
3.4 Thrombosis Markers
Description of Biomarkers and Genetic Markers
-D-Dimer
-Factor V Leiden
-Prothrombin Factor II (PT 20210A)
-Methylene-tetra-hydro-folate-reductase (MTHFR) Gene
-Plaminogen Activator Inhibitor-1
Medical and Economic Impact
Competition and Outlook
3.5 Potential Future Markers for Stroke
Description of Potential Stroke Markers
-Neuron-Specific Enolase
-S-100B
-Matrix Metalloproteinases
-Stroke Panel
Medical and Economic Impact
Competition and Outlook
3.6 Cardio-Theranostics
Pharmacogenetics
-Cytochrome P450
-CYP2D6
-CYP2C9
-Cholesterol Ester Transfer Protein
-Angiotensin-Converting Enzyme Gene
-Beta-1 and Beta-2 Adrenergic Receptor Gene
-N-Acetyltransferase-2 Gene
-Platelet Fc-Gamma-Receptor Gene
-Alpha-Adducin Gene Variant
-Apolipoprotein E Genotyping
Other Cardio-Theranostics
-Antiplatelet Drug Testing
-Aspirin Resistance Test
Medical and Economic Impact
Competition and Outlook
Chapter 4. Expert Interviews
Cardiovascular In Vitro Diagnostic Interviews
-Alberto Abate, bioMérieux
-Kenneth F. Buechler, PhD, Biosite
-Hans-Juergen Loyda, Roche Diagnostics
-David Ludvigson, Nanogen, Inc.
--Biomarker Tests
--Genomic Testing
-- New Biomarkers
Cardiovascular Imaging Interviews
-James Kronauge, PhD, Molecular Insight
-Gregg Mayer, EPIX Pharmaceuticals
Chapter 5. Company Profiles
Abaxis
Abbott Diagnostics
Atherotech
Bayer HealthCare
Beckman Coulter
Berlex Laboratories, Inc.
bioMérieux SA
Biosite
Bracco Diagnostics
Bristol Myers Squibb Medical Imaging
Cholestech
Dade Behring
Diagnostic Products Corp. (DPC)
GE Healthcare
Instrumentation Laboratory
International Technidyne Corp (ITC)
Ischemia Technologies
LipoScience
Mallinkrodt
Nanogen
Ortho Clinical Diagnostics
Philips Medical Systems
Response Biomedical
Roche Diagnostics
Siemens Medical Solutions
Spectral Diagnostics
Sysmex
Third Wave Technology
References
Index
|
|
|
